New Publication from Dr. Thomas Kislinger and Dr. Laurie Ailles
MBP researchers Dr. Thomas Kislinger and Dr. Laurie Ailles have released a new publication titled "N-Glycoproteomics of Patient-Derived Xenografts: A Strategy to Discover Tumor-Associated Proteins in High-Grade Serous Ovarian Cancer".
In this article, they describe an integrated strategy for the systematic detection of tumor-associated proteins from high-grade serous ovarian cancer PDX models and the development of targeted proteomics assays for quantification in longitudinal serum cohorts.
Synopsys - High-grade serous ovarian carcinoma (HGSC) is the most common and lethal subtype of gynecologic malignancy in women. The current standard of treatment combines cytoreductive surgery and chemotherapy. Despite the efficacy of initial treatment, most patients develop cancer recurrence, and 70% of patients die within 5 years of initial diagnosis. CA125 is the current FDA-approved biomarker used in the clinic to monitor response to treatment and recurrence, but its impact on patient survival is limited, and as a result, new strategies for the discovery of HGSC biomarkers are urgently needed. In this article, they describe a proteomics strategy to detect tumor-associated proteins in serum of HGSC patient-derived xenograft models, demonstrating proof-of-concept applicability using two independent, longitudinal serum cohorts from HGSC patients.